Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:MRK

Merck & Company (MRK)

114.20
+0.33 (0.29%)
as of Jun 18, 2026, 11:15:03 pm Market Open.
161 watching
0
BUY
Demographics for pharmaceuticals is good. Could be volatile during their election period. Good long term.
BUY
Likes the valuations. Good balance sheet and good earnings.
BUY
Outlook for drug companies is good. A bit expensve, but long term is good.
BUY
Sector has been hit hard. At a good level. Prefers Pfizer.
PAST TOP PICK
(Was a top pick on Apr 4 up 1.5%) Still likes.
DON'T BUY
Very reasonable valuation. Patents are coming off. Prefers Pfizer.
DON'T BUY
Fairly cheap. Dividend. Several drugs coming off patent.
BUY
At a 5 year low. Have some good products. At a good price.
WEAK BUY
Expiring patents have created problems. Pipeline is not as strong as other pharmaceuticals, but the price is very cheap.
TOP PICK
One of the cheapest in the drug sctor.
DON'T BUY
Losing a lot of their patents with nothing new in the pipeline.
WEAK BUY
No earnings growth this year. Should be some in 2003. At a good price. Prefers J&J or Pfizer.
DON'T BUY
Broke through a technical base. Generics are giving some tough competition.
DON'T BUY
A lot of their drugs have come off patent without adequate replacement. Prefers Pfizer.
WAIT
Competition. Pipeline is weak now. OK long term.
Showing 226 to 240 of 252 entries